)
)
Company research20 Mar 2024
Companies That Had Their IPO in 1987: From Optimism to Black Monday
An overview of 1987's IPO landscape and stock market sentiment, as conditions turned from unabridged optimism to panic in the wake of Black Monday.
Pfizer
Pfizer (PFE) investor relations material
Pfizer U.S. All Stars Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.U.S. All Stars Conference summary22 Sep, 2026
Strategic portfolio evolution and commercial focus
Refocused resources on high-potential products and key markets, cutting unproductive investments and improving commercial efficiency.
New and reacquired products grew from $0.5B in 2023 to $4B, while OpEx was significantly reduced.
COVID franchise was scaled down from $11B in 2024 to a $4B guidance for 2026, reallocating efforts to new growth platforms.
Sales organization productivity tripled in three years through focused deployment and advanced analytics.
Commercial models now emphasize targeted launches and resource allocation in top-performing countries.
Pipeline development and growth outlook
31 phase III clinical studies are ongoing, with a pipeline structured around areas of competitive strength, especially oncology.
Growth is driven by both new launches and pipeline maturation, with $13B in new/acquired product sales and strong market share gains in key therapies.
Oncology pipeline targets high-impact tumor types, leveraging established commercial and medical infrastructure.
Chronic weight management and GLP-1 assets are prioritized, with a portfolio approach to address diverse patient needs.
Portfolio management now emphasizes early signals and swing factors to optimize capital allocation and accelerate promising assets.
Market dynamics and pricing environment
Most Favored Nation (MFN) agreements reduced tariff risks and prompted global moves toward fairer innovation pricing.
Governments in the UK and Japan are adjusting policies to better support innovative medicines, including inflation adjustments and reduced clawbacks.
The rise of China as a biotech powerhouse is reshaping the global landscape, with 50% of ADC and bispecific clinical studies now run in China.
European and Japanese innovation is challenged by talent migration to the US, driven by better pricing and recognition.
Regulatory and patent reforms in Europe are improving the environment for biotech and pharma innovation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pfizer
- LOEs pressured results as vaccine growth supported narrowed FY14 EPS guidance.PFE
Q3 2014 - FY17 adjusted EPS rose 11%; FY18 guidance targets another 11% growth.PFEQ4 2017
- 2017 guidance targets $2.50–$2.60 adjusted EPS amid $4.5B in headwinds.PFEQ4 2016
- Revenue rose 11% and adjusted EPS 14%; 2016 guidance was reaffirmed.PFEQ2 2016
- Adjusted EPS rose 5% to $0.67 as 2017 guidance midpoint increased $0.02.PFEQ2 2017
- Adjusted EPS rose 10% as FY guidance midpoint increased to $2.60.PFEQ3 2017
- Adjusted EPS rose to $0.69 as Innovative Health growth offset Essential Health declines.PFEQ1 2017
- Adjusted EPS rose 16%; FY revenue guidance narrowed amid LOE and supply pressures.PFEQ3 2018
- Adjusted EPS rose 21%; guidance increased as FX cut the revenue outlook.PFEQ2 2018
- Adjusted EPS rose 12% as key-brand growth offset Essential Health pressure.PFEQ1 2018
Next Pfizer earnings date
Q3 20263 Nov, 2026
Pfizer
Next Pfizer earnings date
Q3 20263 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
Related articles
)
Company research17 Jan 2024
The Largest Announced M&A Deals of 2023
Explore the biggest M&A deals of 2023, including major moves in energy, tech, and biotech sectors, reflecting a trend in strategic growth.
)
Company research26 Jun 2023
Class of 2013: A Journey Through the IPO Landscape of 2013
The year 2013 was a pivotal period in the world of business and finance. The global economy was recovering from the 2008 financial crisis, and companies were eager to capitalize on the renewed investor confidence. Among these were several game-changers and industry disruptors that chose 2013 to make their mark on the stock market
Frequently asked questions
A Pharmaceutical Powerhouse
Pfizer is a global pharmaceutical corporation headquartered in New York City. Founded in 1849, it is one of the largest pharmaceutical companies in the world. The company is known for the development and distribution of healthcare solutions across a broad range of therapeutic areas. Pfizer's portfolio includes medicines, vaccines, and consumer health products aimed at improving patient health and well-being.
From Chemicals to Combatting Covid
Founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, Pfizer began as a manufacturer of fine chemicals. The company expanded over the decades, becoming a multinational corporation that now stands as one of the world's largest pharmaceutical companies. It has introduced a number of notable drugs to the market, including Lipitor, Viagra, and Zoloft. In 2020, in response to the global COVID-19 pandemic, Pfizer collaborated with BioNTech and developed a vaccine that became one of the first to receive emergency use authorization worldwide.
From Serious Conditions to Minor Issues
Pfizer's product portfolio encompasses a wide range of medical needs, from treating serious illnesses to addressing minor health conditions. For life-threatening diseases such as cancer, Pfizer offers oncology drugs designed to improve survival rates and quality of life. On the other end of the spectrum, the company also provides over-the-counter consumer healthcare products for everyday ailments like pain, colds, and digestive issues.
Serving Patients Worldwide
Like many other pharmaceutical companies, with Eli Lilly being a good example, Pfizer's operations are widespread, extending to more than 125 countries across the globe. The company maintains a robust distribution network that ensures a wide reach for its products. Its global operations encompass research and development, manufacturing, marketing, and distribution of a broad range of pharmaceuticals and health solutions. This means that patients located in different countries have access to more or less the same offerings of medications, local regulations permitting.